Mesa Laboratories, Inc.
76.71-1.20 (-1.54%)
Oct 29, 4:00:01 PM EDT · NasdaqGS · MLAB · USD
Key Stats
Market Cap
422.02MP/E (TTM)
-Basic EPS (TTM)
-0.13Dividend Yield
0.01%Recent Filings
8-K
Mesa's annual meeting outcomes
Mesa Laboratories held its annual shareholder meeting on August 22, 2025, electing John J. Sullivan, Gary M. Owens, Jenny S. Alltoft, Shannon M. Hall, Shiraz S. Ladiwala, R. Tony Tripeny, and Mark C. Capone to its board for a one-year term. Shareholders ratified Baker Tilly US, LLP as independent auditors for the fiscal year ending March 31, 2026, approved executive compensation on a non-binding basis, and passed an amendment to the 2021 Equity Incentive Plan. All proposals garnered strong support, with over 90% votes in favor for director elections and ratification. The refreshed board signals steady governance continuity.
8-K
Mesa repays notes via credit draw
Mesa Laboratories drew $97 million under its existing credit facility on August 12, 2025, to repay $97.5 million in maturing convertible notes on August 15, leaving $108 million outstanding at a 7.18% rate maturing April 5, 2029. This move optimizes the capital structure, slashing dilution risks while leveraging strong cash flows for $20 million in principal payments through fiscal 2026. Interest costs will dip with rate cuts. Debt service fits comfortably.
8-K
Q1 revenues up 2.4%
Mesa Laboratories reported first-quarter fiscal 2026 revenues of $59.5 million, up 2.4% from last year, with core organic growth at 0.4%. Strong SDC and CS divisions drove gains, yet CG slumped 10.7% amid China contraction and tariffs, while BPD dipped 7.0% from shipment delays. Adjusted operating income fell 15.9% to $12.9 million, pressured by FX and costs. Management eyes revenue goals for the half-year, with Q2 profitability rebound expected. Tariffs hit 1% of revenues.
10-Q
Q1 FY2026 results
Mesa Laboratories posted Q1 FY2026 revenues of $59.5M, up 2.4% y/y but flat q/q, with gross margins dipping to 62.0% from 64.0% y/y amid tariff pressures and mix shifts, while operating income fell 45.1% y/y to $3.1M due to higher expenses. Yet net income jumped 40.0% y/y to $4.7M, boosted by $6.1M in foreign currency gains from a weaker USD; diluted EPS rose to $0.85 from $0.62, reconciling cleanly to 5,553 diluted shares with no anti-dilution flags. Key drivers included 10.7% y/y growth in Sterilization and Disinfection Control consumables, offset by 9.7% declines in Clinical Genomics from China regulatory uncertainty. Liquidity holds at $21.3M cash and $111M revolver availability, with total debt at $176.8M including $97.5M maturing convertible notes; free cash flow came in at $0.9M (derived). In April 2025, the company settled a $9.6M GKE acquisition holdback in cash. Tariffs pose ongoing cost risks.
8-K
Auditor merger prompts switch
Mesa Laboratories switched auditors on June 3, 2025, after Moss Adams merged into Baker Tilly US, LLP, with the Audit Committee approving the seamless transition. No disagreements or reportable events marred the prior year's audit, which cleared without qualifications. Clean handover. This maintains reporting continuity amid the firm's integration.
IPO
Website
Employees
Sector
Industry
A
Agilent Technologies, Inc.
143.20-2.65
BIO
Bio-Rad Laboratories, Inc.
319.47-10.95
LAB
Standard BioTools Inc.
1.19-0.08
MASS
908 Devices Inc.
7.69-0.30
MKSI
MKS Inc.
141.40+0.92
MTD
Mettler-Toledo International, I
1394.17-10.41
SCND
Scientific Industries, Inc.
0.67+0.00
TECH
Bio-Techne Corp
62.02-1.92
TMO
Thermo Fisher Scientific Inc
558.31+0.68
WAT
Waters Corporation
343.47-2.48